Cargando…

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV), first approved in 2017, has high, long-lasting efficacy against herpes zoster (HZ) and a clinically acceptable safety profile. In addition to the prevention of HZ in adults aged ≥50 years, the non-live RZV can be used from age 18 years in...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, R, Widenmaier, R, Weller, R, Lecrenier, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594798/
http://dx.doi.org/10.1093/eurpub/ckac129.728
_version_ 1784815511938269184
author Parikh, R
Widenmaier, R
Weller, R
Lecrenier, N
author_facet Parikh, R
Widenmaier, R
Weller, R
Lecrenier, N
author_sort Parikh, R
collection PubMed
description BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV), first approved in 2017, has high, long-lasting efficacy against herpes zoster (HZ) and a clinically acceptable safety profile. In addition to the prevention of HZ in adults aged ≥50 years, the non-live RZV can be used from age 18 years in individuals with immunocompromised (IC) conditions. We reviewed the evolving landscape of national recommendations for RZV use. METHODS: National health authority and vaccination committee websites of countries where RZV is approved were searched in March 2022. RESULTS: Of 41 countries where RZV is licensed, 14 (Australia, Austria, Canada, Czech Republic, Germany, Ireland, Italy, Netherlands, New Zealand, Saudi Arabia, Spain, Switzerland, UK, US) provide national recommendations related to RZV; the majority are preferential to RZV or only recommend RZV. Overall, seven and seven countries recommend immunisation from age 50 years or 60/65 years, respectively. Of the seven countries that recommend immunisation from age 60/65 years, five recommend immunisation in individuals from age 50 years with comorbidities/IC conditions. Five countries recommend immunisation from age 18/19 years in individuals at increased risk of HZ due to immunosuppressive disease/treatment. In addition, six national recommendations refer to RZV safety and nine address prior HZ vaccination and/or infection. All recommendations outlined the RZV administration schedule. CONCLUSIONS: Although national recommendations can inform decision making in clinical practice, RZV recommendations are not available in all licensed countries. The recommendations highlight a trend in favour of the use of RZV for the prevention of HZ in older individuals and those with IC conditions. Main messages: An increasing number of countries are providing recommendations for the use of RZV for the prevention of HZ in older individuals and those with IC conditions. KEY MESSAGES: • An increasing number of countries are providing recommendations for the use of RZV for the prevention of HZ in older individuals. • An increasing number of countries are providing recommendations for the use of RZV for the prevention of HZ in IC conditions.
format Online
Article
Text
id pubmed-9594798
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95947982022-11-22 An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller Parikh, R Widenmaier, R Weller, R Lecrenier, N Eur J Public Health Parallel Programme BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV), first approved in 2017, has high, long-lasting efficacy against herpes zoster (HZ) and a clinically acceptable safety profile. In addition to the prevention of HZ in adults aged ≥50 years, the non-live RZV can be used from age 18 years in individuals with immunocompromised (IC) conditions. We reviewed the evolving landscape of national recommendations for RZV use. METHODS: National health authority and vaccination committee websites of countries where RZV is approved were searched in March 2022. RESULTS: Of 41 countries where RZV is licensed, 14 (Australia, Austria, Canada, Czech Republic, Germany, Ireland, Italy, Netherlands, New Zealand, Saudi Arabia, Spain, Switzerland, UK, US) provide national recommendations related to RZV; the majority are preferential to RZV or only recommend RZV. Overall, seven and seven countries recommend immunisation from age 50 years or 60/65 years, respectively. Of the seven countries that recommend immunisation from age 60/65 years, five recommend immunisation in individuals from age 50 years with comorbidities/IC conditions. Five countries recommend immunisation from age 18/19 years in individuals at increased risk of HZ due to immunosuppressive disease/treatment. In addition, six national recommendations refer to RZV safety and nine address prior HZ vaccination and/or infection. All recommendations outlined the RZV administration schedule. CONCLUSIONS: Although national recommendations can inform decision making in clinical practice, RZV recommendations are not available in all licensed countries. The recommendations highlight a trend in favour of the use of RZV for the prevention of HZ in older individuals and those with IC conditions. Main messages: An increasing number of countries are providing recommendations for the use of RZV for the prevention of HZ in older individuals and those with IC conditions. KEY MESSAGES: • An increasing number of countries are providing recommendations for the use of RZV for the prevention of HZ in older individuals. • An increasing number of countries are providing recommendations for the use of RZV for the prevention of HZ in IC conditions. Oxford University Press 2022-10-25 /pmc/articles/PMC9594798/ http://dx.doi.org/10.1093/eurpub/ckac129.728 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Parallel Programme
Parikh, R
Widenmaier, R
Weller, R
Lecrenier, N
An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
title An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
title_full An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
title_fullStr An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
title_full_unstemmed An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
title_short An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
title_sort update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: romy weller
topic Parallel Programme
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594798/
http://dx.doi.org/10.1093/eurpub/ckac129.728
work_keys_str_mv AT parikhr anupdateonnationalrecommendationsfortheuseoftheadjuvantedrecombinantzostervaccineromyweller
AT widenmaierr anupdateonnationalrecommendationsfortheuseoftheadjuvantedrecombinantzostervaccineromyweller
AT wellerr anupdateonnationalrecommendationsfortheuseoftheadjuvantedrecombinantzostervaccineromyweller
AT lecreniern anupdateonnationalrecommendationsfortheuseoftheadjuvantedrecombinantzostervaccineromyweller
AT parikhr updateonnationalrecommendationsfortheuseoftheadjuvantedrecombinantzostervaccineromyweller
AT widenmaierr updateonnationalrecommendationsfortheuseoftheadjuvantedrecombinantzostervaccineromyweller
AT wellerr updateonnationalrecommendationsfortheuseoftheadjuvantedrecombinantzostervaccineromyweller
AT lecreniern updateonnationalrecommendationsfortheuseoftheadjuvantedrecombinantzostervaccineromyweller